Effect of oral sodium bicarbonate on fibroblast growth factor-23 in patients with chronic kidney disease: a pilot study

Table 3 Sensitivity analysis after excluding participants on vitamin D

FGF23 (RU/mL)	Before sodium bicarbonate^a	After sodium bicarbonate	p-value
Taking vitamin D^b
Yes (n = 9)	217.0 (146.4–353.2)^*	327.4 (231.7–410.9)	0.31
No (n = 20)	121.2 (85.1–162.4)^*	147.4 (107.0–196.5)	0.08
Taking paricalcitol
Yes (n = 3)	353.2 (98.9–824.9)^**	399.1 (327.4–410.9)	0.59
No (n = 17)	146.4 (116.5–217.0)^**	185.7 (129.9–238.4)	0.009
Increased paricalcitol dose
Yes (n = 1)^c	98.8	399.1	N/A
No (n = 19)	155.5 (116.5–286.5)	186.4 (129.9–306.4)	0.08
Participant #16^d
Yes (n = 1)	824.9	410.9	N/A
No (n = 19)	146.4 (98.8–248.3)	186.4 (129.9–306.4)	0.01

FGF23 was expressed in median (interquartile range)
Abbreviation: N/A not applicable
^*p-value comparing FGF23 between those taking vitamin D and those not taking vitamin D = 0.06
^**p-value comparing FGF23 between those taking paricalcitol and those not taking paricalcitol = 0.02
^aVariables for “before sodium bicarbonate” were the mean of values between the initial visit and after 2-week placebo
^bVitamin D used included ergocalciferol, cholecalciferol and paricalcitol
^cParticipant #3 had paricalcitol dose increased during the study
^dParticipant #16 had very a high FGF23 level at baseline

ISSN: 1471-2369